Home › Companies › AKBA

Akebia Therapeutics

AKBA Rare disease Lead: Approved 3 Biotech Distilled articles ↓

Hematology Ophthalmology Renal Respiratory Protein Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (10 active programs)

Vafseo

vadadustat

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase

Anemia Due to Chronic Kidney Disease Approved oral

Auryxia

ferric citrate

Hyperphosphatemia Approved oral
Iron Deficiency Anemia Approved oral

praliciguat

Small Molecule Target: sGC, soluble guanylate cyclase

Focal Segmental Glomerulosclerosis Phase 2 oral Cyclerion Therapeutics

AKB-097

Protein Target: C3d, Factor H

AKB-9090

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase

AKB-10108

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase

Retinopathy of Prematurity Preclinical

Biotech Distilled coverage (3)

2026-06-30 UPDATE: Akebia Therapeutics (AKBA) - VOICE Stops Early
2026-05-08 UPDATE: Akebia Therapeutics (AKBA) - The Receipts Arrive 🔒 Paid
2026-03-04 Akebia (AKBA): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.